ORCID Profile
0000-0002-5569-3559
Current Organisation
University of Zürich
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Chemical Society (ACS)
Date: 05-10-2020
DOI: 10.26434/CHEMRXIV.13023164.V1
Abstract: The apparent “boosted mobility” observed by nuclear magnetic resonance (NMR) diffusion measurements is the result of a known artefact. When signal intensities are changing during an NMR diffusion measurement for reasons other than diffusion, the use of monotonically increasing gradient litudes produces erroneous diffusion coefficient values. We show that no boosted molecular mobility is observed when shuffled gradient litudes are applied.
Publisher: Cold Spring Harbor Laboratory
Date: 18-10-2017
DOI: 10.1101/205203
Abstract: Pharmacological inhibition of uncontrolled cell growth with small molecule inhibitors is a potential strategy against glioblastoma multiforme (GBM), the most malignant primary brain cancer. Phenotypic profiling of the neurogenic small molecule KHS101 revealed the chemical induction of lethal cellular degradation in molecularly- erse GBM cells, independent of their tumor subtype, whereas non-cancerous brain cells remained viable. Mechanism-of-action (MOA) studies showed that KHS101 specifically bound and inhibited the mitochondrial chaperone HSPD1. In GBM but not non-cancerous brain cells, KHS101 elicited the aggregation of an enzymatic network that regulates energy metabolism. Compromised glycolysis and oxidative phosphorylation (OXPHOS) resulted in the metabolic energy depletion in KHS101-treated GBM cells. Consistently, KHS101 induced key mitochondrial unfolded protein response factor DDIT3 in vitro and in vivo , and significantly reduced intracranial GBM xenograft tumor growth upon systemic administration, without discernible side effects. These findings suggest targeting of HSPD1-dependent oncometabolic pathways as an anti-GBM therapy.
Publisher: American Chemical Society (ACS)
Date: 05-10-2020
DOI: 10.26434/CHEMRXIV.13023164
Abstract: The apparent “boosted mobility” observed by nuclear magnetic resonance (NMR) diffusion measurements is the result of a known artefact. When signal intensities are changing during an NMR diffusion measurement for reasons other than diffusion, the use of monotonically increasing gradient litudes produces erroneous diffusion coefficient values. We show that no boosted molecular mobility is observed when shuffled gradient litudes are applied.
Publisher: American Association for the Advancement of Science (AAAS)
Date: 15-01-2021
Abstract: The apparent “boosted mobility” observed by Wang et al . (Reports, 31 July 2020, p. 537) is the result of a known artifact. When signal intensities are changing during a nuclear magnetic resonance (NMR) diffusion measurement for reasons other than diffusion, the use of monotonically increasing gradient litudes produces erroneous diffusion coefficients. We show that no boosted molecular mobility is observed when shuffled gradient litudes are applied.
No related grants have been discovered for paul chumas.